Graft Versus Host Disease Treatment Market is projected to reach US$ 5,655.37 million by 2032

The global Graft Versus Host Disease Treatment Market sales is expected to reach US$ 5,655.37 million by 2032, with an 8.3% compound annual growth rate (CAGR). Because of the increased use of corticosteroids and combination medications to treat Graft Versus Host Disease in hematopoietic cell transplant (HCT) patients, the market has been gradually growing. The market value is expected to be US$ 2,547.86 million in 2022, with a 7.8% growth rate observed from 2016 to 2021.

Recent advances in overall survival and acute Graft Versus Host Disease severity levels have benefited patients having allogeneic hematopoietic cell transplant, although several difficulties remain. Newer drugs, like as Jakafi and Rezurock, have been licenced for the prevention and treatment of chronic Graft Versus Host Disease, and they may be more effective than previous medications.

Request a Sample to Obtain Analysis and Comprehensive Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1401

In December 2021, the US Food and Drug Administration approved Orencia (abatacept) for the treatment of GRAFT VERSUS HOST DISEASE in adults and pediatric patients. In addition to treating autoimmune disorders, Orencia can also prevent them. By binding to and modulating one of the main costimulation signals sent by T-cells, Orencia prevents full activation of T-cells, thus preventing acute Graft Versus Host Disease. Doctors are currently evaluating new approaches to prevent Graft Versus Host Disease in the future.

The approval of Orencia is expected to increase access to stem cell transplants for a larger number of cancer patients and individuals with blood disorders, particularly those from diverse ethnic backgrounds. Future treatments may include immunosuppression and other agents such as regenerative or tissue-repairing agents to improve treatment response in Graft Versus Host Disease patients.

Key Takeaways

• According to the study, North America is predicted to lead the global graft versus host disease (Graft Versus Host Disease) therapy market throughout the forecast period.
• During the forecast period, Europe is expected to be the second-largest market, according to the report.
• The adoption of various Graft Versus Host Disease treatments is likely to boost the market and account for the largest share in 2022.
• Monoclonal antibodies are likely to earn considerable market share in the future years, according to Future Market Insights.

Ask More About This Market’s Geographical Distribution Along With a Detailed Analysis of the Top Regions@ https://www.futuremarketinsights.com/ask-question/rep-gb-1401

Regional Insights

North America is expected to dominate the global graft versus host disease (Graft Versus Host Disease) treatment market during the forecast period, as per the analysis. In 2022, the region is projected to account for about 34% of the total market share. A well-established medical infrastructure and the presence of major key players in the region have contributed to its dominance in the (Graft Versus Host Disease) treatment market.

The United States is expected to be the largest contributor to market development during the forecast period, driven by growing awareness of Graft Versus Host Disease and the availability of new medicines that are expected to propel market growth. Regulatory approval of various medicines is also expected to contribute to the region’s growth.

Europe is projected to be the second-largest market during the forecast period, estimated to hold 21% of the total market share in 2022. The growth of the market in Europe can be attributed to the rapid development of the food and beverage sector in the region.

Competition Analysis

Key players in the global graft versus host disease (Graft Versus Host Disease) treatment market include Sanofi, Equillium, Inc., Novartis AG, Neovii Biotech GmbH,Merck & Co., Astellas Pharma Inc.,Soligenix, Inc., Mesoblast Ltd, Pfizer, Takeda Pharmaceutical, Abbott, and others.

• Equillium, Inc. announced the start of the EQUATOR study in March 2022, a pivotal Phase 3 clinical research of itolizumab in patients with acute graft-versus-host disease (Graft Versus Host Disease). In a randomised, double-blind research, itolizumab will be compared to placebo as first-line therapy for (Graft Versus Host Disease) combination with corticosteroids.
• Novartis announced the European Commission (EC) approval of Jakavi (ruxolitinib) in May 2022 for the treatment of patients aged 12 years and older with acute or chronic (Graft Versus Host Disease) who have not responded adequately to corticosteroids or other systemic therapies. With Jakavi, a novel technique to control (Graft Versus Host Disease) that is debilitating and life-threatening is now possible, qualifying as a new choice for healthcare providers and patients.

Buy Now to Gain Access to Detailed Information About Each Segment and Identify Key Trends, Drivers, and Challenges in the Market@ https://www.futuremarketinsights.com/checkout/1401

Key Segments Profiled In The Global Graft Versus Host Disease Treatment Market

Graft Versus Host Disease Treatment Market by Product:

• Monoclonal antibodies Graft Versus Host Disease Treatment
• mTOR inhibitors Graft Versus Host Disease Treatment
• Tyrosine kinase inhibitors Graft Versus Host Disease Treatment
• Thalidomide Graft Versus Host Disease Treatment
• Etanercept Graft Versus Host Disease Treatment

Graft Versus Host Disease Treatment Market by Disease:

• Acute Graft Versus Host Disease
• Chronic Graft Versus Host Disease

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs